Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Perrigo (PRGO) stock in plain English

Free brief · no signupStart here
PRGOPublished Nov 19, 2026
Perrigo Company plc
Healthcare · Drug Manufacturers - Specialty & Generic
Produces over-the-counter pain relievers, allergy treatments, infant formulas, and oral hygiene goods for major retailers.
Assets:
25 manufacturing facilitiesOperates pharmaceutical and formula plants across North America and Europe.
9,000 employeesStaffs product research, regulatory compliance, and packaging lines.
Private-label OTC supplyPackages store-brand medications for retailers like Walmart and CVS.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

44
OPS ScoreOperating finances
Latest quote
-5.31%$16.04
$2.23B
n/a (loss)
$4.12B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PRGO. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Perrigo (PRGO) do?

Perrigo Company plc (PRGO) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Produces over-the-counter pain relievers, allergy treatments, infant formulas, and oral hygiene goods for major retailers. Produces private-label over-the-counter medications and self-care products for pharmacies and grocery chains. It is worth $2.23B on the market and sold $4.12B over the last year.

Market cap
$2.23B
P/E ratio
None (reported a loss)
Annual sales
$4.12B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 19, 2026

Brands and businesses behind PRGO

  • Opill: Sells over-the-counter daily oral contraceptive pills through pharmacies and retail stores.
  • Compeed: Sells hydrocolloid blister patches and foot care products in retail pharmacies across Europe.
  • Mederma: Generates revenue by selling topical scar treatment gels, creams, and skin protectants to consumers.
  • ellaOne: Sells emergency contraceptive tablets directly to consumers through retail pharmacies across Europe.
  • Physiomer: Generates revenue by selling isotonic and hypertonic seawater nasal sprays for respiratory care.
  • Paranix: Sells non-chemical head lice treatment shampoos and sprays to retail consumers in European markets.

PRGO’s flags, in plain English

Each flag is a number from Perrigo’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Pays You to Hold

Pays a 7.23% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Stupid Cash

Can pay this year's bills 2.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Cheap on Cash Flow

Priced at 13.2 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Debt Is Driving

Heavy debt, 142% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about PRGO

How big is Perrigo?

Perrigo’s market cap is $2.23B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $4.12B: what customers paid the company over the last year, before any costs.

What is PRGO’s P/E ratio?

PRGO has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with PRGO?

Perrigo carries over 4 billion dollars in debt incurred from acquisitions of branded self-care companies. That is one risk on Perrigo’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Perrigo’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PRGO’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card